News Quantified

NEO – neogenomics, inc. (US:NASDAQ)

NeoGenomics, Inc. (NASDAQ: NEO) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $17.00 to $15.00. They now have a "buy" rating on the stock.

4/8

08:32 am

neo

Medium

Freenome Names Aaron Elliott, Ph.D., as Chief Executive Officer to Lead the Company's Next Chapter of Commercial Growth and Product Innovation [Yahoo! Finance]

NeoGenomics to Report First Quarter 2025 Financial Results on April 29, 2025 [Yahoo! Finance]

NeoGenomics to Report First Quarter 2025 Financial Results on April 29, 2025

NeoGenomics Completes Acquisition of Pathline

Live Event: Join our next subscriber-only event: "The Data Driven Investor"

Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

52 Week High	{{GetCompanyStockInfo.Week52HighValue}} {{GetCompanyStockInfo.Week52HighDate}}
52 Week Low	{{GetCompanyStockInfo.Week52LowValue}} {{GetCompanyStockInfo.Week52LowDate}}

Today’s Volatility	{{VolatilityStr}}
20 Day Volatility	{{Volatility20Str}}

Open	{{GetCompanyStockInfo.Open}}
Prior Close	{{GetCompanyStockInfo.PriorCloseValue}} {{GetCompanyStockInfo.PriorCloseDate}}